Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001213900-26-059134
Filing Date
2026-05-19
Accepted
2026-05-19 17:19:52
Documents
2

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0291449-8k_vaxart.htm DEFA14A 20077
2 PRESS RELEASE, DATED MAY 19, 2026 ea029144901ex99-1.htm EX-99.1 57045
  Complete submission text file 0001213900-26-059134.txt   78430
Mailing Address 310 UTAH AVENUE, SUITE 150 SOUTH SAN FRANCISCO CA
Business Address 310 UTAH AVENUE, SUITE 150 SOUTH SAN FRANCISCO CA (650) 550-3500
Vaxart, Inc. (Filer) CIK: 0000072444 (see all company filings)

EIN.: 591212264 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-35285 | Film No.: 261000359
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)